Invesaro

Stocks Comparison

Myriad Genetics vs Trinity Biotech: revenue, profit, margins and growth compared

Myriad Genetics brought in $824.5M of revenue in fiscal 2025, Trinity Biotech $61.6M in fiscal 2024. Revenue changed by -1.6% at Myriad Genetics and +8.3% at Trinity Biotech on the year before, so Trinity Biotech grew faster. Myriad Genetics kept -44.4% of its revenue as net profit, Trinity Biotech -51.6%.

Side by side, latest fiscal year

MYGNTRIB
Fiscal year endedFY2025 (December 31, 2025)FY2024 (December 31, 2024)
Revenue$824.5M$61.6M
Revenue growth-1.6%+8.3%
Net income-$365.9M-$31.8M
Net margin-44.4%-51.6%
Free cash flown/a-$4.6M
Free cash flow marginn/a-7.5%
Earnings per share (diluted)-$3.95n/a
Cash$149.6M$5.2M
Debt$119.9Mn/a
Price to earningsn/an/a
Market value$398.9M$5.5M
Dividend yieldn/an/a
Rank by revenue in sector#160 of 646 · Health care#358 of 646 · Health care

Over the years

Revenue
MYGN FY2019: $851.1MMYGN FY2020: $638.6MMYGN FY2020: $557.1MMYGN FY2021: $690.6MMYGN FY2022: $678.4MMYGN FY2023: $753.2MMYGN FY2024: $837.6MMYGN FY2025: $824.5MTRIB FY2017: $99.1MTRIB FY2018: $97MTRIB FY2019: $90.4MTRIB FY2020: $102MTRIB FY2021: $81.1MTRIB FY2022: $62.5MTRIB FY2023: $56.8MTRIB FY2024: $61.6MFY17FY18FY19FY20FY21FY22FY23FY24FY25
MYGN $824.5MTRIB $61.6M
Net income
MYGN FY2019: $4.6MMYGN FY2020: -$199.5MMYGN FY2020: -$223.6MMYGN FY2021: -$27.2MMYGN FY2022: -$112MMYGN FY2023: -$263.3MMYGN FY2024: -$127.3MMYGN FY2025: -$365.9MTRIB FY2017: -$40.3MTRIB FY2018: -$22.1MTRIB FY2019: -$28.9MTRIB FY2020: -$6.4MTRIB FY2021: $875KTRIB FY2022: -$41MTRIB FY2023: -$24MTRIB FY2024: -$31.8MFY17FY18FY19FY20FY21FY22FY23FY24FY25
MYGN -$365.9MTRIB -$31.8M
Net margin
MYGN FY2019: 0.5%MYGN FY2020: -31.2%MYGN FY2020: -40.1%MYGN FY2021: -3.9%MYGN FY2022: -16.5%MYGN FY2023: -35.0%MYGN FY2024: -15.2%MYGN FY2025: -44.4%TRIB FY2017: -40.6%TRIB FY2018: -22.8%TRIB FY2019: -32.0%TRIB FY2020: -6.3%TRIB FY2021: 1.1%TRIB FY2022: -65.6%TRIB FY2023: -42.3%TRIB FY2024: -51.6%FY17FY18FY19FY20FY21FY22FY23FY24FY25
MYGN -44.4%TRIB -51.6%
Revenue growth
MYGN FY2020: -25.0%MYGN FY2020: -12.8%MYGN FY2021: +24.0%MYGN FY2022: -1.8%MYGN FY2023: +11.0%MYGN FY2024: +11.2%MYGN FY2025: -1.6%TRIB FY2018: -2.1%TRIB FY2019: -6.8%TRIB FY2020: +12.8%TRIB FY2021: -20.4%TRIB FY2022: -23.0%TRIB FY2023: -9.1%TRIB FY2024: +8.3%FY18FY19FY20FY21FY22FY23FY24FY25
MYGN -1.6%TRIB +8.3%
Free cash flow
MYGN FY2019: $75.1MMYGN FY2020: $50.5MMYGN FY2021: $600KMYGN FY2022: -$151.6MTRIB FY2017: $4.4MTRIB FY2018: -$299KTRIB FY2019: $3.3MTRIB FY2020: $20.6MTRIB FY2021: $11.4MTRIB FY2022: -$2MTRIB FY2023: -$12.4MTRIB FY2024: -$4.6MFY17FY18FY19FY20FY21FY22FY23FY24
MYGN -$151.6MTRIB -$4.6M

Fiscal years as each company reports them; the two may end in different months.

Questions about Myriad Genetics and Trinity Biotech

Which is bigger by revenue, Myriad Genetics or Trinity Biotech?

Myriad Genetics is bigger by revenue: $824.5M in fiscal 2025, against $61.6M for Trinity Biotech in fiscal 2024.

Which keeps more of its revenue as profit, Myriad Genetics or Trinity Biotech?

Myriad Genetics had a net margin of -44.4% in fiscal 2025; Trinity Biotech had -51.6% in fiscal 2024.

Which grew revenue faster, Myriad Genetics or Trinity Biotech?

In their latest fiscal years revenue changed by -1.6% at Myriad Genetics and +8.3% at Trinity Biotech.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies